

**Supplemental figure 1. Biophysical characterization of full nanobody panel.** (a) Gating for yeast surface display selections. (b) Tabulated averaged melting temperatures for all nanobody candidates are represented in a table  $\pm$  SD.

**Supplemental figure 2. Quantified colony formation screen.** (a) Bar graph of full colony formation screen for all 11 nanobodies, analyzed using a one-way ANOVA (N=8, error bars  $\pm$  SD). (\*  $p < 0.0332$ , \*\*  $p < 0.0021$ , \*\*\*  $p < 0.0002$ , \*\*\*\*  $p < 0.0001$ ).

**Supplemental figure 3. Apoptosis screen for full panel of nanobodies.** (a) Apoptosis screen for all 11 nanobodies in (a) CaSki and (b) C33A was analyzed using a one-way ANOVA (N=3, error bars  $\pm$  SD). (b) Significant nanobodies from the CaSki screen were further screened in C33A HPV(-) cervical cancer cells (N=3, error bars  $\pm$  SD) and analyzed with a one-way ANOVA. (c) Flow cytometry gating schema for the apoptosis screen. (d) Representative dot plots for CaSki and C33A cell lines in apoptosis screen with Empty control and A2 nanobody. (\*  $p < 0.0332$ , \*\*  $p < 0.0021$ , \*\*\*  $p < 0.0002$ , \*\*\*\*  $p < 0.0001$ ).

**Supplemental figure 4. ISG56 screen and dose-dependent relationship of nanobody C11.** HEK293T cells were transfected with expression plasmids encoding N-RIG-I, TRIM25, USP15, pISG56-luc, and HPV16 E6 without and with (a) the full range of nanobodies or (b) increasing concentrations of the C11 E6-targeting nanobodies as indicated. Luciferase activities were normalized by co-transfection with pRL-TK. Cell lysates were collected after 24 h and luciferase activities were determined by Dual Luciferase Assay (Promega). Shown are the means  $\pm$  SD of triplicate samples for one of three representative experiments (N=3).

**Supplemental figure 5. PROTAC<sup>E6</sup> induction of IFNB mRNA levels.** The induction of IFNB mRNA was measured using RT-qPCR (N=3). A one-way ANOVA was performed, and error bars represent  $\pm$  SD. (\*  $p < 0.0332$ , \*\*  $p < 0.0021$ , \*\*\*  $p < 0.0002$ , \*\*\*\*  $p < 0.0001$ ).

**Supplemental figure 6. Mouse body weight.** Mouse body weight was recorded throughout treatment and plotted (N=5).

Supplemental Material:

Reagent	Company	Catalogue number
Yeast surface display library	Andy Kruse	Requested
Propidium iodide	BD Bioscience	556463
Annexin-V-APC	BioLegend	640920
$\alpha$ -CD4 (GK1.5)	Bio Cell	BE0003
$\alpha$ -CD8 (2.43)	Bio Cell	BE0061
In vivo JetPEI	PolyPlus Transfections	201-50G
CaSki	ATCC	CRM-CRL-1550
C33A	ATCC	HTB-31
HEK293T	Eric Lau (GeneHunter)	Requested
pcDNA-Xpress-His-USP15	Addgene	23216
pFlagCMV2-EFP	Addgene	12449
P1322 HPV16-E6	Addgene	8642

Table of primers:

Target	Forward 5'-3'	Reverse 5'-3'
ISG15	GAGAGGCAGCGAACTCATCT	CTTCAGCTCTGACACCGACA
IFNB	CTTGGATTCTACAAAGAAGCAGC	TCCTCCTTCTGGAAGTCTGCA
GAPDH	GTCTCCTCTGACTTCAACAGCG	ACCACCCTGTTGCTGTAGCCAA
Yeast pYAL F	CCTCTATACTTTAACGTCAAGGAG	-